Guidelines Updated for Use of Antiplatelet Therapy for Atherosclerotic CVD

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 19, 2023.

By Elana Gotkine HealthDay Reporter

TUESDAY, Dec. 19, 2023 (HealthDay News) -- In a guideline update issued by the Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology and published online Oct. 28 in the Canadian Journal of Cardiology, new recommendations are presented regarding the use of antiplatelet therapy (APT) for the prevention of atherosclerotic cardiovascular disease.

Kevin R. Bainey, M.D., from the Mazankowski Alberta Heart Institute at the University of Alberta in Edmonton, Canada, and colleagues updated guidelines for the use of APT for primary and secondary prevention of atherosclerotic cardiovascular disease.

The guidelines provide recommendations relating to the use of acetylsalicylic acid in the primary prevention of atherosclerotic cardiovascular disease; duration of dual APT (DAPT) after percutaneous coronary intervention (PCI) in patients with a high risk for bleeding; choice of potent DAPT (P2Y12 inhibitor) for patients presenting with an acute coronary syndrome (ACS) and possible DAPT de-escalation strategies after PCI; choice and duration of DAPT in patients with ACS who are treated medically, without revascularization; and DAPT pretreatment before coronary angiography. In addition, recommendations also address perioperative and longer-term APT management for those who need coronary artery bypass grafting surgery, as well as the use of APT for patients with atrial fibrillation who require oral anticoagulation after PCI or ACS with medical management.

"We really focus on individuals and determining their cardiovascular risk, their risk of bleeding, and then tailoring their antiplatelet therapy to maximize the outcomes for them," Bainey said in a statement. "So, it's really taking it to a different level; we're the first in the world to endorse a shared decision-making model, engaging the person who is at risk together with their doctor."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords